NASDAQ:ME 23andMe (ME) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ME Stock Alerts $0.53 +0.02 (+3.91%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.52▼$0.5550-Day Range$0.40▼$0.8152-Week Range$0.40▼$2.32Volume4.89 million shsAverage Volume6.63 million shsMarket Capitalization$256.91 millionP/E RatioN/ADividend YieldN/APrice Target$1.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get 23andMe alerts: Email Address 23andMe MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside228.9% Upside$1.75 Price TargetShort InterestHealthy11.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 10 Articles This WeekInsider TradingSelling Shares$97,141 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.91 out of 5 starsMedical Sector429th out of 938 stocksPharmaceutical Preparations Industry207th out of 441 stocks 3.5 Analyst's Opinion Consensus Rating23andMe has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.75, 23andMe has a forecasted upside of 228.9% from its current price of $0.53.Amount of Analyst Coverage23andMe has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.03% of the float of 23andMe has been sold short.Short Interest Ratio / Days to Cover23andMe has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in 23andMe has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield23andMe does not currently pay a dividend.Dividend Growth23andMe does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ME. Previous Next 3.2 News and Social Media Coverage News Sentiment23andMe has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for 23andMe this week, compared to 7 articles on an average week.Search Interest24 people have searched for ME on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added 23andMe to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 23andMe insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $97,141.00 in company stock.Percentage Held by Insiders27.55% of the stock of 23andMe is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.10% of the stock of 23andMe is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 23andMe is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 23andMe is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio23andMe has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About 23andMe Stock (NASDAQ:ME)23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Read More ME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ME Stock News HeadlinesMarch 23, 2024 | insidertrades.comInsider Selling: 23andMe Holding Co. (NASDAQ:ME) Insider Sells 38,548 Shares of StockMarch 28, 2024 | msn.comTalking to someone online for emotional support may be riskier than you realizeMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 28, 2024 | msn.comNeo-Nazi who inspired American History X is now an orthodox JewMarch 28, 2024 | msn.comWhen her doctor doubted the severity of her morning sickness, this geneticist and Time Woman of the Year found the cause herselfMarch 26, 2024 | msn.comWant to upload your DNA to help with genetic genealogy? Here's how.March 25, 2024 | americanbankingnews.com23andMe Holding Co. (NASDAQ:ME) Insider Sells $17,732.08 in StockMarch 24, 2024 | fool.comBillionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?March 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 22, 2024 | yahoo.comDNA testing can find hidden connections - ErvolinoMarch 21, 2024 | ca.style.yahoo.comAmazon Big Spring Sale: This 23andMe kit is 'super informative' — and it's on saleMarch 21, 2024 | msn.comDNA Tests Like 23AndMe Are Revealing Disturbing Family Connections, Including Related LoversMarch 20, 2024 | globenewswire.com23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6March 19, 2024 | dailymail.co.ukDNA tests like 23AndMe and Ancestry are laying bare the frightening extent of incest in the US - including woman who discovers her ex-lover was her BROTHERMarch 19, 2024 | globenewswire.com23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years AgoMarch 18, 2024 | msn.comThis Risk Assessment Tool Helped Olivia Munn Catch Her Breast Cancer EarlyMarch 18, 2024 | msn.comIn 'an act of freedom', Brunswick County residents discover African ancestryMarch 16, 2024 | news.yahoo.comDog DNA Company Insists Human DNA Is Actually Alaskan MalamuteMarch 16, 2024 | venturebeat.comDecoding the data dilemma: Strategies for effective data deletion in the age of AIMarch 16, 2024 | msn.comMethods for Authenticating Data Breach AuthenticityMarch 16, 2024 | yahoo.comHow to verify a data breachMarch 16, 2024 | finance.yahoo.comME Apr 2024 0.500 callMarch 16, 2024 | finance.yahoo.comME Apr 2024 1.500 putMarch 15, 2024 | forbes.com5 Questions To Ask About The Ethics Of Genetic DataMarch 14, 2024 | msn.comWedle: Family Name, Meaning, History, and MoreMarch 14, 2024 | yahoo.comWALK THE WALK: A special presentation from Dr. Noura Abul-Husn from 23andmeMarch 14, 2024 | cbsnews.comFamily of 1972 Naperville, Illinois murder victim finally has "closure" with suspect deadSee More Headlines Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/07/2024Today3/29/2024Fiscal Year End3/31/2024Next Earnings (Estimated)5/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ME CUSIPN/A CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees769Year FoundedN/APrice Target and Rating Average Stock Price Target$1.75 High Stock Price Target$1.75 Low Stock Price Target$1.75 Potential Upside/Downside+228.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,660,000.00 Net Margins-210.48% Pretax Margin-210.71% Return on Equity-52.99% Return on Assets-39.32% Debt Debt-to-Equity RatioN/A Current Ratio2.15 Quick Ratio2.04 Sales & Book Value Annual Sales$299.49 million Price / Sales0.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book0.34Miscellaneous Outstanding Shares482,920,000Free Float349,873,000Market Cap$256.91 million OptionableNot Optionable Beta1.28 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Anne WojcickiCo-Founder, CEO, President & Chair of the BoardMr. Joseph Selsavage (Age 61)Interim CFO & Accounting Officer Comp: $574.56kMs. Kathy L. Hibbs Esq. (Age 60)J.D., Chief Administrative Officer & Corporate Secretary Comp: $699.8kMr. Guy ChayounVice President & Interim General CounselMs. Katie Watson (Age 46)Vice President of Communications Mr. Jonathan WardChief Marketing OfficerMr. Reza Afkhami M.B.A.Chief Corporate Development OfficerMs. Savita PillaiVice President of PeopleDr. Jennifer Low (Age 55)Head of Therapeutics Development Mr. Kent Hillyer (Age 56)Vice President of Consumer Operations More ExecutivesKey CompetitorsTrevi TherapeuticsNASDAQ:TRVIFibroGenNASDAQ:FGENXBiotechNASDAQ:XBITVerrica PharmaceuticalsNASDAQ:VRCAAtossa TherapeuticsNASDAQ:ATOSView All CompetitorsInsiders & InstitutionsKathy L HibbsSold 38,548 sharesTotal: $17,732.08 ($0.46/share)Vanguard Group Inc.Sold 5,591,112 shares on 3/11/2024Ownership: 4.670%Goldman Sachs Group Inc.Sold 90,953 shares on 3/1/2024Ownership: 0.106%American International Group Inc.Bought 19,663 shares on 2/28/2024Ownership: 0.031%Virtu Financial LLCBought 113,705 shares on 2/26/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions ME Stock Analysis - Frequently Asked Questions Should I buy or sell 23andMe stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 23andMe in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ME shares. View ME analyst ratings or view top-rated stocks. What is 23andMe's stock price target for 2024? 1 analysts have issued 12 month price targets for 23andMe's stock. Their ME share price targets range from $1.75 to $1.75. On average, they predict the company's stock price to reach $1.75 in the next year. This suggests a possible upside of 228.9% from the stock's current price. View analysts price targets for ME or view top-rated stocks among Wall Street analysts. How have ME shares performed in 2024? 23andMe's stock was trading at $0.9135 at the start of the year. Since then, ME shares have decreased by 41.8% and is now trading at $0.5320. View the best growth stocks for 2024 here. When is 23andMe's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our ME earnings forecast. How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) issued its quarterly earnings data on Wednesday, February, 7th. The company reported ($0.17) EPS for the quarter. The company had revenue of $44.75 million for the quarter, compared to analyst estimates of $56.30 million. 23andMe had a negative net margin of 210.48% and a negative trailing twelve-month return on equity of 52.99%. What ETFs hold 23andMe's stock? ETFs with the largest weight of 23andMe (NASDAQ:ME) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Global X Telemedicine & Digital Health ETF (EDOC). What guidance has 23andMe issued on next quarter's earnings? 23andMe issued an update on its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $215.0 million-$220.0 million, compared to the consensus revenue estimate of $245.5 million. Who are 23andMe's major shareholders? 23andMe's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.71%), Vanguard Group Inc. (4.67%), Voya Investment Management LLC (1.15%), Northern Trust Corp (0.56%), Charles Schwab Investment Management Inc. (0.51%) and Wittenberg Investment Management Inc. (0.29%). Insiders that own company stock include Kathy L Hibbs, Kenneth J Hillan and William G Richards. View institutional ownership trends. How do I buy shares of 23andMe? Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ME) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.